Profiles

Keywords
Last Name
Institution

The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.

Singh AK. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6.

View in: PubMed

collapse authors with profiles